P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
about
Pharmacokinetic drug-drug interaction and their implication in clinical managementPrediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CNeurologic adverse effects during concomitant treatment with ciprofloxacin, NSAIDS, and chloroquine: possible drug interaction.Syncopal episodes associated with cisapride and concurrent drugs.The physiological and pharmacological roles of cytochrome P450 isoenzymes.Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotypingInhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidineAssessment of drug-drug interactions: concepts and approaches.Metabolic activation of toxins: tissue-specific expression and metabolism in target organs.The inhibition of CYP enzymes in mouse and human liver by pilocarpineInteractions between the cytochrome P450 system and the second-generation antipsychotics.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction.Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.The effect of parenteral nutrition on hepatic cytochrome P-450.Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.In vitro methods for assessing human hepatic drug metabolism: their use in drug development.Treatment of rhinitis.The assessment of flavin-containing monooxygenase activity in intact animals.The human drug metabolizing cytochromes P450.The pharmacokinetics of Casodex enantiomers in subjects with impaired liver functionMeta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites.Variability in activity of hepatic CYP3A4 in patients infected with HIV.Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.Toxicokinetics of organic solvents: a review of modifying factors.Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.
P2860
Q27021051-7FB0F3EF-F6C6-4F06-9EDE-1567E17E5637Q30981419-68BBA8EB-63EF-4B71-974F-914C6C1936BDQ33174236-06FCC9D2-4118-403D-A48A-9F95F18A365AQ33175671-8DE5A4D8-F976-43ED-A0D0-1455D0B3AE48Q33597477-AC51A7DA-80C3-4739-B52A-FDF5525F14CDQ33921325-64B7EBB0-1A9B-4C95-8AF3-D1A94F7D9CA9Q34346469-4A4FFF59-5BFE-4326-BD9B-EAE4F45259BCQ34378923-48550935-C3DA-4EB5-80A2-BF449DF55898Q34638922-61BED3CA-7F87-4A93-9964-3C2C5DDEF938Q34792764-41F4B30F-F352-4C47-9066-EA6CF6BE302CQ35096587-0CB4D827-1A0B-4CEC-A6A1-9625213F636FQ35236618-1D90CB6A-13ED-4FB0-93C9-F599BDB6008EQ36055154-AD9D42ED-D42D-49F5-985D-6063957D0B8EQ36178387-4BD77258-EE3F-45B6-96A5-2ECEE0621742Q36895764-D8A7CF3B-47CA-40CC-A225-C7E1B41807A6Q36953062-A231B660-9B6F-4597-A7A3-8089E0061BD7Q40565626-E5AEC5DE-8B44-4CE1-AB06-0B0C5448169EQ40815580-4B80F241-DE95-410E-8434-DF5D437D200CQ40817420-CE4C4ED0-ED51-4057-AE28-7D60B5A51DDAQ41097554-7010E5E3-85A6-46EA-9570-9BDD05FD7577Q41197123-8A884678-D9F6-4495-AB0B-BBCD98F803E7Q41456105-365E73EB-A665-40D1-85D9-E92349ABD5BCQ41984799-B692A509-A746-43CB-891F-6588F4F4CE00Q44569647-2AED9621-97ED-497E-A3F2-81EE00500339Q44874904-EC822422-3A95-4E1D-9EC6-E27F2CC713EFQ46836748-4E73F663-8E87-4F36-B08F-48E748E2FF53Q49166540-B03C4C7C-3B4E-4058-872B-F04ECE198020Q50851509-7BE2EE42-4835-47A1-B0FD-CC7B66D345C5Q53343412-84A4F7E9-87B3-4847-9BA3-2BA5FB459908
P2860
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
@ast
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
@en
type
label
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
@ast
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
@en
prefLabel
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
@ast
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
@en
P1476
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
@en
P2093
P304
P356
10.2165/00003088-199223020-00005
P577
1992-08-01T00:00:00Z
P6179
1041378843